GlassScriptPhysician profile
James Michael Wilson
NPI 1184627317
$10,876.01
in general payments reported to CMS, 2019-2025
36 companies · $1,465 in 2025
The $1,465 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,638 · 2020: $992 · 2021: $1,391 · 2022: $2,020 · 2023: $1,951 · 2024: $1,420 · 2025: $1,465.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,835.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,834.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,245.77 | 2019-2025 | Rinvoq, Skyrizi |
| Amgen INC. | $1,988.81 | 2019-2025 | Evenity, Otezla, Otezla |
| Janssen Biotech, INC. | $1,223.57 | 2020-2025 | Tremfya, Simponi Aria, Remicade |
| Novartis Pharmaceuticals Corporation | $730.12 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $574.08 | 2021-2025 | Saphnelo |
| Ucb, INC. | $550.81 | 2019-2025 | Cimzia, Bimzelx |
| Pfizer INC. | $520.44 | 2019-2025 | |
| Lilly USA, LLC | $469.83 | 2020-2023 | Taltz |
| Janssen Scientific Affairs, LLC | $445.85 | 2021-2022 | |
| Glaxosmithkline, LLC. | $374.32 | 2019-2025 | Benlysta |
| Alexion Pharmaceuticals, INC. | $222.79 | 2022-2025 | Strensiq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $170.24 | 2021-2024 | Ofev, Cyltezo |
| E.R. Squibb & Sons, L.L.C. | $156.25 | 2019-2021 | |
| Organon LLC | $154.59 | 2021-2024 | Hadlima |
| Radius Health, INC. | $133.74 | 2021-2025 | Tymlos |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $122.06 | 2019 | |
| Mallinckrodt Hospital Products INC. | $118.01 | 2020-2023 | Acthar |
| Genzyme Corporation | $111.52 | 2020-2024 | |
| Horizon Therapeutics Plc | $100.08 | 2019-2022 | |
| Scilex Pharmaceuticals INC. | $86.56 | 2024-2025 | |
| Ani Pharmaceuticals, INC. | $63.72 | 2025 | Purified Cortrophin Gel |
| Zimmer Biomet Holdings, INC. | $37.00 | 2025 | Rosa |
| Ibsa Pharma INC. | $31.22 | 2022-2023 | Tirosint, Licart |
| Kiniksa Pharmaceuticals International, Plc | $26.78 | 2024 | Arcalyst |
| Mallinckrodt Enterprises LLC | $22.93 | 2019 | |
| Depuy Synthes Sales INC. | $22.79 | 2019 | |
| Sandoz INC. | $20.73 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $20.46 | 2023 | Opsumit, Uptravi |
| Aurinia Pharma U.S., INC. | $19.88 | 2025 | Lupkynis |
| Bioventus LLC | $19.33 | 2021 | |
| Genentech USA, INC. | $19.06 | 2024 | Erivedge |
| Tersera Therapeutics LLC | $16.73 | 2022 | |
| Fresenius Kabi USA, LLC | $15.49 | 2025 | |
| Avion Pharmaceuticals | $14.18 | 2020 | |
| Merck Sharp & Dohme LLC | $14.13 | 2020 | |
| Zyla Life Sciences, INC. | $12.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.